February'24 Edition
The potential of Generative AI in the generation of novel small molecules
The emergence of generative AI models has instigated a significant shift in the creation of novel small molecule entities. A recent approach to small molecule design draws inspiration from text-to-image modeling software, exemplified by DALL-E and Midjourney, enabling the generation of small molecules based on textual prompts.
Enki Technology platform empowers users to input target product profiles (TPPs) and desired attributes, facilitating the generation of small molecules tailored to specific criteria. It generates synthesizable lead-like structures based on the specified desired targets, exclusions, and other attributes provided by the user, prompting the generation of molecules that adhere to the TPP criteria.
Boltchem is an advanced AI chemistry studio that incorporates a suite of generative algorithms trained on decades of experimental data. The platform offers users the capability to customize small molecules according to their desired specifications and focus on a selected chemical space. It streamlines property prediction, molecular exploration, virtual screening, and lead optimization.?
To know more about Boltchem book a demo at Boltchem-demo
AI and Robotic Technology in Automating Chemistry & Transforming synthesis
A groundbreaking innovation in chemical synthesis, “RoboChem” is an innovative autonomous chemical synthesis robot developed by Professor Timothy No?l's group at the UvA's Van ‘t Hoff Institute for Molecular Sciences. This new technology operates autonomously, delivering results swiftly and with remarkable precision while minimizing waste. Its ability to conduct various chemical reactions and provide insights for scaling up processes is particularly beneficial for industries like pharmaceuticals, where efficient production is essential.
This revolutionary technique replaces conventional glassware with a sophisticated system of small, adaptable tubes, redefining the landscape of chemical reactions. Central to this method is a meticulously engineered robotic needle, programmed to precisely collect and blend starting materials in small volumes before directing them through the tubing system to the reactor. Within this reactor, molecular transformations are initiated using the power of light emitted by potent LEDs, which activate a photocatalyst integrated into the reaction mixture. This strategic use of light marks a significant departure from traditional methods, offering a more controlled and efficient approach to chemical synthesis.
Try ReBolt, an AI-assisted tool for synthesis planning that recommends synthesis pathways of molecules from the ground up listing the byproducts and intermediates steps and links to purchase the reagents and starting materials. It allows the user to make decisions on pathways to be followed on multiple fronts whether that be the availability of starting materials, the expenses, or the resources involved.
Sign up for ReBolt at ReBolt.
Reference: https://www.nature.com/articles/d41586-024-00093-w ? ? ? ? ? ? ? ? ? ? https://www.science.org/doi/10.1126/science.adj1817
领英推荐
Revolutionary vaccine strategy harnesses flu immunity for rapid defense against new threats!
A groundbreaking approach to vaccine design is emerging, leveraging the body's existing immunity against influenza to provide swift protection against newly emerging pathogens. This innovative strategy capitalizes on the conserved components of the influenza virus, known as "stalk" proteins, which remain relatively stable across different strains. By incorporating these universal elements into the vaccine, researchers aim to harness the body's pre-existing immunity against influenza, providing a head start in mounting a rapid and effective response against a broad spectrum of emerging pathogens.
This design offers a timely solution to the challenges posed by rapidly evolving infectious agents, enabling a more agile response to emerging threats. Traditional vaccine development often requires substantial time and resources, hampering swift reactions to novel pathogens. Leveraging the immune memory built through influenza exposure allows for a quicker adaptation of the immune system to combat new infectious agents.
In essence, this novel vaccine design not only enhances our ability to respond promptly to emerging pathogens but also showcases a forward-thinking approach to vaccine development, ushering in a new era of agility and effectiveness in the face of evolving global health challenges.
Try Boltpro, an AI platform that can aid vaccine development by analyzing vast datasets, predicting potential antigens, and simulating immune responses. We contribute to the understanding of vaccine safety, efficacy, and post-marketing surveillance through data analysis and real-time monitoring.
Try the Beta version at BoltPro
AI-Powered Early Detection of Pancreatic Cancer
The characteristic of Pancreatic Ductal Adenocarcinoma (PDAC) to remain asymptomatic until the later advanced stages is a major contributing factor to the high associated mortality. Currently, available screening techniques primarily focus on individuals with a genetic predisposition or a family history of cancer, thereby neglecting a significant portion (approximately 90%) of actual cases. This calls for an urgent need for enhanced screening methods targeting the general population to address this deadly disease and improve outcomes.
Researchers at MIT used electronic health records (EHRs) from 55 healthcare organizations (HCOs) across the US to develop machine learning models that predict PDAC risk 6–18 months in advance. Data from TriNetX's federated EHR database platform was leveraged to build the model ensuring that the patient data had sufficient medical history for accurate prediction. Features such as basic diagnosis, medication, and lab features were extracted from the electronic health records (EHR).?
The team trained and assessed two types of models: neural networks (PrismNN) and logistic regression (PrismLR). Features derived from patient records were used to predict pancreatic cancer risk 6–18 months in advance. The model was able to identify PDAC high-risk individuals from the general population who can then be referred for further screening. This innovative approach paves the way for expanding the screening population beyond those with inherited predispositions, potentially improving early detection rates. The model has the potential to become an important step in the clinical setting to improve the adoption of treatment strategies based on patient profiles.?
ClinBolt, a digital twin of individual patients designed for tailoring individual treatments based on personalized data including medical history, genomic data, demographics, and more.
Please write to us at [email protected] to learn more about ClinBolt.